Why the study?
Does DMP754 or XV459 prevent arterial thrombosis compared to aspirin, heparin, or ticlopidine in canine models?
Population
Canine models of arterial thrombosis
Comparison
DMP754 and XV459 given intravenously or orally vs Aspirin, heparin, or ticlopidine
Design
Preclinical
Authors
Loading...
Animal data support advancing these agents to human trials; leaves open translation of antithrombotic efficacy to clinical practice.
Does DMP754 or XV459 prevent arterial thrombosis compared to aspirin, heparin, or ticlopidine in canine models?
DMP754 (roxifiban) and its active form XV459 demonstrate potent intravenous and oral antithrombotic efficacy in canine models, outperforming standard agents like aspirin, heparin, and ticlopidine.
Mousa et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: